Comparison of pain outcomes between two anti-GD2 antibodies in patients with neuroblastoma

Doralina L. Anghelescu, Jacob L. Goldberg, Lane G. Faughnan, Jianrong Wu, Shenghua Mao, Wayne L. Furman, Victor M. Santana, Fariba Navid

Research output: Contribution to journalArticlepeer-review

50 Scopus citations


Addition of anti-GD2 antibody ch14.18 to the treatment of neuroblastoma has improved outcomes. The most common side effect of ch14.18 is neuropathic pain, which may in part be complement-mediated. Hu14.18K322A is a humanized anti-GD2 antibody designed to diminish complement activation and induce less pain. We compare the pain outcomes in patients treated with ch14.18 and those treated with hu14.18K322A, and explore dose-dependent relationships between pain scores, opioid requirements, and complement levels in patients treated with hu14.18K322A. Procedure: Opioid (morphine equivalent mg/kg) and anxiolytic requirements during course 1 (4 days) in patients treated with hu14.18K322A and ch14.18 were reviewed. Correlations between antibody dose and pain scores, opioid requirements, and complement levels were examined for patients receiving hu14.18K322A. Results: Patients treated with hu14.18K322A (n=19) had lower opioid requirements than those who received ch14.18 (n=9). The differences in median opioid requirements (mg/kg) were statistically significant for the overall course (1.57 vs. 2.41, P=0.019) as well as for Days 3 (0.34 vs. 0.65, P=0.005), and 4 (0.32 vs. 0.64, P=0.010). No difference in anxiolytic use was observed between the two groups. In the group treated with hu14.18K322A, we found a positive correlation between antibody dose administered and pain scores, but no correlation between antibody dose and opioid requirements or changes in complement levels. Conclusions: In this retrospective analysis, hu14.18K322A induced less pain than ch14.18 based on opioid requirements.

Original languageEnglish
Pages (from-to)224-228
Number of pages5
JournalPediatric Blood and Cancer
Issue number2
StatePublished - Feb 1 2015

Bibliographical note

Publisher Copyright:
© 2014 Wiley Periodicals, Inc.


  • Anti-GD2 antibodies
  • Neuroblastoma
  • Opioids
  • Pain
  • Pediatric oncology

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology


Dive into the research topics of 'Comparison of pain outcomes between two anti-GD2 antibodies in patients with neuroblastoma'. Together they form a unique fingerprint.

Cite this